Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Co., Ltd.
  6. Nieuws
  7. Persberichten
    4568   JP3475350009

DAIICHI SANKYO CO., LTD.

(4568)
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť DAIICHI SANKYO CO., LTD.
18/01Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Ph..
BU
18/01†Cosette Pharmaceuticals Acquires Rights to Eight Branded Products from Daiichi Sankyo
BU
17/01Enhertu granted Priority Review in the US for patients with HER2-positive metastatic br..
AQ
2021Daiichi Sankyo Authorizes the First YESCARTA (Axicabtagene Ciloleucel) CAR T-cell Thera..
AQ
2021DAIICHI SANKYO : "R&D Day 2021"
PU
2021Enhertu additional analyses further reinforce ground-breaking efficacy in patients with..
AQ
2021Japanese drugmaker Daiichi Sankyo sets up subsidiary in Singapore
AQ
2021DAIICHI SANKYO : Corporate Governance Report
PU
2021DAIICHI SANKYO : Astrazeneca - Enhertu granted Breakthrough Therapy Designation in US for ..
AQ
2021DAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72% vs. trast..
AQ
2021DAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9% in patie..
AQ
2021DAIICHI SANKYO : Enhertu demonstrated clinically meaningful and durable response in patien..
AQ
2021DAIICHI SANKYO : ENHERTUģ Reduced the Risk of Disease Progression or Death by 72% Versus T..
BU
2021Defence therapeutics selects the best 8 accumtm variants to optimize its adc therapeuti..
AQ
2021LOGICBIO THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Highlights Recen..
AQ
2021DAIICHI SANKYO : Enhertu significantly improved progression-free survival in DESTINY-Breas..
AQ
2021DAIICHI SANKYO : ENHERTUģ Significantly Improved Progression-Free Survival in DESTINY-Brea..
BU
2021DAIICHI SANKYO : Consolidated Financial Results for the First Three Months of the Year End..
PU
2021DAIICHI SANKYO : Top Management Presentation
PU
2021DAIICHI SANKYO : Reference Data
PU
2021DAIICHI SANKYO : Corporate Governance Report
PU
2021CHICAGO LEADING THE WAY : New Educational Collaboration Seeks to Create a Clinical Action ..
AQ
2021DAIICHI SANKYO : Announces the Introduction of a Trust-type Share-based Compensation Syste..
PU
2021DAIICHI SANKYO : Announces Changes to Representative Directors, Directors and Audit & Supe..
PU
2021DAIICHI SANKYO : Japanese drugmaker starts AstraZeneca vaccine production in Japan
AQ
2021DAIICHI SANKYO : Enhertu approved in the US for the treatment of patients with previously ..
AQ
2021DAIICHI SANKYO : AstraZeneca to showcase transformative data across diverse pipeline at Wo..
AQ
2020ESPERION THERAPEUTICS : Daiichi Sankyo - First-in-class cholesterol-lowering treatment NIL..
AQ
2020DAIICHI SANKYO : AstraZeneca - Trastuzumab deruxtecan recommended for approval in the EU b..
AQ
2020DAIICHI SANKYO : AstraZeneca - Enhertu continues to demonstrate durable responses with new..
AQ
2020DAIICHI SANKYO : Creates New Business Unit to Unify Major Oncology Markets into One Stream..
AQ
2020DAIICHI SANKYO : Successfully Defends Itself Against An Early Market Entry Of Generic Comp..
AQ
2020BioInvent Interim Report January 1 - September 30, 2020
AQ
2020DAIICHI SANKYO : RedHill Biopharma Adds Israel Rights to Movantik from AstraZeneca
AQ
2020DAIICHI SANKYO : Announces Establishment of DAIICHI SANKYO VIETNAM COMPANY LIMITED
AQ
2020DAIICHI SANKYO : Submits Supplemental Application in Japan for Approval of Partial Changes..
AQ
2020DAIICHI SANKYO : AnHeart Licenses Two Clinical Stage Oncology Candidates from Daiichi Sank..
AQ
2020DAIICHI SANKYO : Announces Results of Phase 3 Clinical Trial for Anticoagulant Edoxaban
AQ
2020DAIICHI SANKYO : Selected for AMED's 'Development of a Vaccine for COVID-19 Vaccines
AQ
2020DAIICHI SANKYO : Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patri..
AQ
2020DAIICHI SANKYO : Selected as Provider for Japanese Government's 'Emergent Initiative to Bu..
AQ
2020DAIICHI SANKYO : RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movanti..
AQ
2020DAIICHI SANKYO : and AstraZeneca Enter New Global Development and Commercialization Collab..
AQ
2020DAIICHI SANKYO : and AstraZeneca Enter New Global Development and Commercialization Collab..
BU
2020DAIICHI SANKYO : Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Throm..
AQ
2020DAIICHI SANKYO : EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxteca..
AQ
2020DAIICHI SANKYO : Announces Participation in AMR Action Fund
AQ
2020DAIICHI SANKYO : EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxteca..
AQ
2020DAIICHI SANKYO : Announces Start of Discussions with AstraZeneca Regarding Supply in Japan..
AQ
2020DAIICHI SANKYO : Personal Jurisdiction Win In Pennsylvania
AQ
2020DAIICHI SANKYO : Announces Decision to Develop Vaccine in Japan for Novel Corona Virus Inf..
AQ
2020NICHI IKO PHARMACEUTICAL : The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Re..
AQ
2020DAIICHI SANKYO : Announces Clinical Research Collaboration to Evaluate DS-1062 in Combinat..
AQ
2020DAIICHI SANKYO : AstraZeneca - Enhertu significantly improved tumour response rate and ove..
AQ
2020DAIICHI SANKYO : AstraZeneca and Daiichi Sankyo Company, Limited - Enhertu achieved a tumo..
AQ
2020DAIICHI SANKYO : AstraZeneca - Enhertu demonstrated meaningful clinical activity in patien..
AQ
2020DAIICHI SANKYO : Launches ENHERTU in Japan for Patients with HER2 Positive Unresectable or..
AQ
2020DAIICHI SANKYO : ENHERTU Granted Orphan Drug Designation in the U.S. for Gastric Cancer
AQ
2020DAIICHI SANKYO : Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with..
AQ
2020DAIICHI SANKYO : ENHERTU Granted Orphan Drug Designation in the U.S. for Gastric Cancer
AQ
2020DAIICHI SANKYO : ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Mut..
AQ
2020DAIICHI SANKYO : AstraZeneca - ENHERTU granted Breakthrough Therapy Designation in the US ..
AQ
2020DAIICHI SANKYO : Enhertu granted Breakthrough Therapy Designation in the US for HER2-mutan..
AQ
2020DAIICHI SANKYO : ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Pos..
AQ
2020DAIICHI SANKYO : Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in J..
BU
2020DAIICHI SANKYO : Announces Removal of Contaminated Soil Storage Facility from Site of Form..
AQ
2020DAIICHI SANKYO : Announces Share Split, Partial Amendment to the Articles of Incorporation..
AQ
2020DAIICHI SANKYO : Contributes to Relief Efforts for Countermeasures against COVID-19
AQ
2020DAIICHI SANKYO : Mitsubishi UFJ Capital and Nagoya Institute of Technology Announce Open I..
AQ
2020DAIICHI SANKYO : and Kitasato Pharmaceutical Industry to End Sales Cooperation for Influen..
AQ
2020DAIICHI SANKYO : ENHERTU Approved in Japan for Treatment of Patients with HER2 Positive Un..
AQ
2020Zymeworks Reports 2019 Year-End Financial Results
AQ
2020DAIICHI SANKYO : UCB Japan Co., Ltd - Anti-epilepsy Drug VIMPAT, Submission for Supplement..
AQ
2020RedHill Biopharma Acquires Rights to Movantik from AstraZeneca
AQ
2020DAIICHI SANKYO : Appoints New Corporate Officers
AQ
1  2  3  4  5  6Volgende
Volgende evenement op DAIICHI SANKYO CO., LTD.
31/01/22
Komende gebeurtenissen in de sector